Ophthalmology in China

Previous Articles     Next Articles

One-year efficacy of intravitreal Conbercept injection for macular edema secondary to central retinal vein occlusion

ZENG Hui-yang, LI Xiao-xia, LIU Qian, XIAO Yuan-yuan, HOU Si-meng.   

  1. Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China
  • Received:2018-07-22 Online:2019-07-25 Published:2019-07-30
  • Contact: ZENG Hui-yang, Email: zhydr@hotmail.com


 Objective To evaluate the 1-year follow-up efficacy of intravitreal injection of Conbercept for treatment of macular edema secondary to central retinal vein occlusion (CRVO). Design Retrospective case series. Participant Twenty-seven eyes in 27 patients with macular edema associated with CRVO were retrospectively reviewed. Methods The CRVO eyes received monthly intravitreal injection of Conbercept (0.5 mg) for 3 months. From then on, the patients were followed up monthly and received PRN injection up to 12 months. Main Outcome Measures Best-corrected visual acuity (BCVA), central retinal thickness (CRT), proportion of patients gaining ≥15 EDTRS letters,the number of total injections in one-year and safty. Results The mean BCVA gain from baseline was 12.7±7.6 letters at month 3 and 14.8±9.6 letters at month 12. The mean CRT reduction from baseline was (374.5±280.7) μm at month 3 and (428.2±241.3) μm at month 12. The proportion of patients who gained ≥15 letters in BCVA was 45.1% at month 3 and 52.9% at month 12. The mean number of injections was 7.6±1.5. No severe local and systemic complications occurred following injection. Conclusion Intravitreal injection of Conbercept by 3+PRN regime was safe and efficacious for treatment of patients with macular edema secondary to CRVO through one-year follow-up. (Ophthalmol CHN, 2019, 28: 254-258)

Key words: central retinal vein occlusion;macular edema, conbercept, intravitreal injection